{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:04:09Z","timestamp":1788951849693,"version":"build-2803163510"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2021,1,5]],"date-time":"2021-01-05T00:00:00Z","timestamp":1609804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Ethics Review Board Sweden","award":["2015\/1844\u201331\/2"],"award-info":[{"award-number":["2015\/1844\u201331\/2"]}]},{"name":"Ethics Review Board Sweden","award":["73\/13\/03\/00\/2014"],"award-info":[{"award-number":["73\/13\/03\/00\/2014"]}]},{"name":"Ethics Review Board Sweden","award":["2011\/1339"],"award-info":[{"award-number":["2011\/1339"]}]},{"name":"Ethics Review Board Sweden","award":["2017\/2041"],"award-info":[{"award-number":["2017\/2041"]}]},{"name":"National Bioethics Committee","award":["VSNb2017010049\/03.01"],"award-info":[{"award-number":["VSNb2017010049\/03.01"]}]},{"name":"Danish Data Protection Agency","award":["HGH-2016\u2013099"],"award-info":[{"award-number":["HGH-2016\u2013099"]}]},{"name":"Danish Data Protection Agency","award":["04972"],"award-info":[{"award-number":["04972"]}]},{"DOI":"10.13039\/501100004836","name":"Danish Council for Independent Research","doi-asserted-by":"crossref","award":["6110\u201300608"],"award-info":[{"award-number":["6110\u201300608"]}],"id":[{"id":"10.13039\/501100004836","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004348","name":"Stockholm County Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To investigate whether TNF inhibitors (TNFi) are associated with increased risk of solid cancer in patients with psoriatic arthritis (PsA).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>From the Nordic clinical rheumatology registers (CRR) here: SRQ\/ARTIS (Sweden), DANBIO (Denmark), NOR-DMARD (Norway), ROB-FIN (Finland) and ICEBIO (Iceland) we identified PsA patients who started a first TNFi 2001\u20132017 (n\u2009=\u20099655). We identified patients with PsA not treated with biologics from (i) the CRR (n\u2009=\u200914\u00a0809) and (ii) the national patient registers (PR, n\u2009=\u200931\u00a0350). By linkage to the national cancer registers, we collected information on incident solid cancer overall and for eight cancer types. We used Cox regression to estimate hazard ratio (HR) with 95% CI of cancer (per country and pooled) in TNFi-exposed vs biologics-na\u00efve, adjusting for age, sex, calendar period, comorbidities and disease activity. We also assessed standardized incidence ratios (SIR) in TNFi-exposed PsA vs the general population (GP).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We identified 296 solid cancers among the TNFi-exposed PsA patients (55\u00a0850 person-years); the pooled adjusted HR for solid cancer overall was 1.0 (0.9\u20131.2) for TNFi-exposed vs biologics-na\u00efve PsA from the CRR, and 0.8 (0.7\u20131.0) vs biologics-na\u00efve PsA from the PRs. There were no significantly increased risks for any of the cancer types under study. The pooled SIR of solid cancer overall in TNFi treated PsA vs GP was 1.0 (0.9\u20131.1).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In this large cohort study from five Nordic countries, we found no increased risk of solid cancer in TNFi-treated PsA patients, neither for solid cancer overall nor for eight common cancer types.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaa828","type":"journal-article","created":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T21:23:08Z","timestamp":1605820988000},"page":"3656-3668","source":"Crossref","is-referenced-by-count":15,"title":["Risk of solid cancers overall and by subtypes in patients with psoriatic arthritis treated with TNF inhibitors \u2013 a Nordic cohort study"],"prefix":"10.1093","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7149-0973","authenticated-orcid":false,"given":"Karin","family":"Hellgren","sequence":"first","affiliation":[{"name":"Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden"},{"name":"Rheumatology, Theme Inflammation & Infection, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Ballegaard","sequence":"additional","affiliation":[{"name":"Bispebjerg and Frederiksberg, The Parker Institute, Copenhagen University Hospital, Hellerup, Denmark"},{"name":"Centre for Rheumatology and Spine Diseases, Rigshospitalet - Gentofte, Hellerup, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Delcoigne","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5271-2574","authenticated-orcid":false,"given":"Ren\u00e9","family":"Cordtz","sequence":"additional","affiliation":[{"name":"Bispebjerg and Frederiksberg, The Parker Institute, Copenhagen University Hospital, Hellerup, Denmark"},{"name":"Centre for Rheumatology and Spine Diseases, Rigshospitalet - Gentofte, Hellerup, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Nordstr\u00f6m","sequence":"additional","affiliation":[{"name":"Department of Medicine and Rheumatology, ROB-FIN, Helsinki University Hospital and Helsinki University, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalle","family":"Aaltonen","sequence":"additional","affiliation":[{"name":"ROB-FIN, Pharmaceuticals Pricing Board, Ministry of Social Affairs and Health, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjorn","family":"Gudbjornsson","sequence":"additional","affiliation":[{"name":"Centre for Rheumatology Research, Landspitali University Hospital, and Faculty of Medicine, Reykjavik, Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorvardur Jon","family":"Love","sequence":"additional","affiliation":[{"name":"Department of Science and Faculty of Medicine, National University Hospital of Iceland, University of Iceland, Reykjavik, Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5442-902X","authenticated-orcid":false,"given":"Sella","family":"Aarrestad Provan","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Sexton","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Zobbe","sequence":"additional","affiliation":[{"name":"Bispebjerg and Frederiksberg, The Parker Institute, Copenhagen University Hospital, Hellerup, Denmark"},{"name":"Centre for Rheumatology and Spine Diseases, Rigshospitalet - Gentofte, Hellerup, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Erik","family":"Kristensen","sequence":"additional","affiliation":[{"name":"Bispebjerg and Frederiksberg, The Parker Institute, Copenhagen University Hospital, Hellerup, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Askling","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden"},{"name":"Rheumatology, Theme Inflammation & Infection, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lene","family":"Dreyer","sequence":"additional","affiliation":[{"name":"Bispebjerg and Frederiksberg, The Parker Institute, Copenhagen University Hospital, Hellerup, Denmark"},{"name":"Department of Rheumatology, Aalborg University Hospital, Aalborg University, Denmark"},{"name":"DANBIO Registry, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,1,5]]},"reference":[{"key":"2021080220014267700_keaa828-B1","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2021080220014267700_keaa828-B2","doi-asserted-by":"crossref","first-page":"i37","DOI":"10.1093\/rheumatology\/kez383","article-title":"Treatment guidelines in psoriatic arthritis","volume":"59","author":"Ogdie","year":"2020","journal-title":"Rheumatology"},{"key":"2021080220014267700_keaa828-B3","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.2217\/fon.10.155","article-title":"TNF: a tumor-suppressing factor or a tumor-promoting factor?","volume":"6","author":"Balkwill","year":"2010","journal-title":"Future Oncol"},{"key":"2021080220014267700_keaa828-B4","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.2741\/3066","article-title":"TNF: a master switch for inflammation to cancer","volume":"13","author":"Sethi","year":"2008","journal-title":"Front Biosci"},{"key":"2021080220014267700_keaa828-B5","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1136\/ard.2008.091025","article-title":"The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events","volume":"68","author":"Leombruno","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2021080220014267700_keaa828-B6","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1001\/2012.jama.10857","article-title":"Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis","volume":"308","author":"Lopez-Olivo","year":"2012","journal-title":"JAMA"},{"key":"2021080220014267700_keaa828-B7","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1136\/ard.2010.149419","article-title":"Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis","volume":"70","author":"Mariette","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2021080220014267700_keaa828-B8","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1002\/art.24941","article-title":"Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?","volume":"60","author":"Askling","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2021080220014267700_keaa828-B9","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/rheumatology\/kes350","article-title":"Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population","volume":"52","author":"Mercer","year":"2013","journal-title":"Rheumatology"},{"key":"2021080220014267700_keaa828-B10","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2012-201969","article-title":"Incidences of overall and site specific cancers in TNFalpha inhibitor treated patients with rheumatoid arthritis and other arthritides - a follow-up study from the DANBIO Registry","volume":"72","author":"Dreyer","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2021080220014267700_keaa828-B11","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s13075-015-0728-9","article-title":"Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis","volume":"17","author":"Simon","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2021080220014267700_keaa828-B12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2036.18.s2.2.x","article-title":"Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease","volume":"18","author":"Munkholm","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"2021080220014267700_keaa828-B13","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s40257-017-0337-2","article-title":"Malignancy risk and recurrence with psoriasis and its treatments: a concise update","volume":"19","author":"Geller","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"2021080220014267700_keaa828-B14","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1001\/jamadermatol.2015.4847","article-title":"The risk of cancer in patients with psoriasis: a population-based cohort study in the health improvement network","volume":"152","author":"Chiesa Fuxench","year":"2016","journal-title":"JAMA Dermatol"},{"key":"2021080220014267700_keaa828-B15","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jamadermatol.2020.0024","article-title":"Prevalence, incidence, and risk of cancer in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"156","author":"Vaengebjerg","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2021080220014267700_keaa828-B16","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/art.23185","article-title":"Prevalence of malignancy in psoriatic arthritis","volume":"58","author":"Rohekar","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2021080220014267700_keaa828-B17","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/art.38385","article-title":"A comparison of the malignancy incidence among patients with psoriatic arthritis and patients with rheumatoid arthritis in a large US cohort","volume":"66","author":"Gross","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2021080220014267700_keaa828-B18","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1007\/s10067-016-3396-5","article-title":"Malignancy incidence in patients with psoriatic arthritis: a comparison cohort-based incidence study","volume":"35","author":"Wilton","year":"2016","journal-title":"Clin Rheumatol"},{"key":"2021080220014267700_keaa828-B19","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/RHU.0000000000000364","article-title":"Rates of cancers and opportunistic infections in patients with psoriatic arthritis compared with patients without psoriatic arthritis","volume":"22","author":"Hagberg","year":"2016","journal-title":"J Clin Rheumatol"},{"key":"2021080220014267700_keaa828-B20","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.semarthrit.2018.05.009","article-title":"Malignancy development risk in psoriatic arthritis patients undergoing treatment: a systematic review and meta-analysis","volume":"48","author":"Luo","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"2021080220014267700_keaa828-B21","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.critrevonc.2016.01.002","article-title":"Alcoholic beverages, obesity, physical activity and other nutritional factors, and cancer risk: A review of the evidence","volume":"99","author":"Latino-Martel","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"2021080220014267700_keaa828-B22","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.3899\/jrheum.090822","article-title":"Cardiovascular disease and risk factors in patients with psoriasis and psoriatic arthritis","volume":"37","author":"Tobin","year":"2010","journal-title":"J Rheumatol"},{"key":"2021080220014267700_keaa828-B23","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.semarthrit.2016.05.012","article-title":"Psoriasis, psoriatic arthritis, and rheumatoid arthritis: is all inflammation the same?","volume":"46","author":"Coates","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"2021080220014267700_keaa828-B24","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1136\/annrheumdis-2016-209270","article-title":"Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers","volume":"76","author":"Hellgren","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2021080220014267700_keaa828-B25","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/rheumatology\/kep423","article-title":"Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for. Rheumatology Biologics Register","volume":"49","author":"Saad","year":"2010","journal-title":"Rheumatology"},{"key":"2021080220014267700_keaa828-B26","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/art.37740","article-title":"Tumor necrosis factor alpha inhibitor therapy and cancer risk in chronic immune-mediated diseases","volume":"65","author":"Haynes","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2021080220014267700_keaa828-B27","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.semarthrit.2010.08.005","article-title":"Cancer in patients with rheumatic diseases exposed to TNF antagonists","volume":"41","author":"Carmona","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"2021080220014267700_keaa828-B28","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/rheumatology\/key241","article-title":"Malignancy and mortality rates in patients with severe psoriatic arthritis requiring tumour-necrosis factor alpha inhibition: results from the British Society for Rheumatology Biologics Register","volume":"58","author":"Fagerli","year":"2019","journal-title":"Rheumatology"},{"key":"2021080220014267700_keaa828-B29","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1136\/ard.2009.117762","article-title":"Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry","volume":"69","author":"Mariette","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2021080220014267700_keaa828-B30","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/ajg.2012.334","article-title":"T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-alpha) inhibitors: results of the REFURBISH study","volume":"108","author":"Deepak","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"2021080220014267700_keaa828-B31","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.cyto.2016.09.013","article-title":"Do tumor necrosis factor inhibitors increase cancer risk in patients with chronic immune-mediated inflammatory disorders?","volume":"101","author":"Chen","year":"2018","journal-title":"Cytokine"},{"key":"2021080220014267700_keaa828-B32","doi-asserted-by":"crossref","first-page":"e000655","DOI":"10.1136\/rmdopen-2018-000655","article-title":"Opportunities and challenges for real-world studies on chronic inflammatory joint diseases through data enrichment and collaboration between national registers: the Nordic example","volume":"4","author":"Chatzidionysiou","year":"2018","journal-title":"RMD Open"},{"key":"2021080220014267700_keaa828-B33","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3109\/03009742.2014.927918","article-title":"How good is the coverage and how accurate are exposure data in the Swedish Biologics Register (ARTIS)?","volume":"44","author":"Wadstrom","year":"2015","journal-title":"Scand J Rheumatol"},{"key":"2021080220014267700_keaa828-B34","doi-asserted-by":"crossref","first-page":"627","DOI":"10.2147\/CLEP.S141438","article-title":"Validity and completeness of rheumatoid arthritis diagnoses in the nationwide DANBIO clinical register and the Danish National Patient Registry","volume":"9","author":"Ibfelt","year":"2017","journal-title":"Clin Epidemiol"},{"key":"2021080220014267700_keaa828-B35","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.semarthrit.2016.09.005","article-title":"Effectiveness and drug survival of TNF-inhibitors in the treatment of psoriatic arthritis: A prospective cohort study","volume":"46","author":"Aaltonen","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"2021080220014267700_keaa828-B36","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1093\/rheumatology\/keu252","article-title":"Impact of different infliximab dose regimens on treatment response and drug survival in 462 patients with psoriatic arthritis: results from the nationwide registries DANBIO and ICEBIO","volume":"53","author":"Glintborg","year":"2014","journal-title":"Rheumatology"},{"key":"2021080220014267700_keaa828-B37","first-page":"S188","article-title":"A Norwegian DMARD register: prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic diseases","volume":"23","author":"Kvien","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"2021080220014267700_keaa828-B38","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1186\/1471-2458-11-450","article-title":"External review and validation of the Swedish national inpatient register","volume":"11","author":"Ludvigsson","year":"2011","journal-title":"BMC Public Health"},{"key":"2021080220014267700_keaa828-B39","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2147\/CLEP.S91125","article-title":"The Danish national patient registry: a review of content, data quality, and research potential","volume":"7","author":"Schmidt","year":"2015","journal-title":"Clin Epidemiol"},{"key":"2021080220014267700_keaa828-B40","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/pds.1294","article-title":"The new Swedish Prescribed Drug Register\u2013opportunities for pharmacoepidemiological research and experience from the first six months","volume":"16","author":"Wettermark","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2021080220014267700_keaa828-B41","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/02841860802247664","article-title":"The completeness of the Swedish Cancer Register: a sample survey for year 1998","volume":"48","author":"Barlow","year":"2009","journal-title":"Acta Oncol"},{"key":"2021080220014267700_keaa828-B42","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1177\/1403494810393562","article-title":"The Danish cancer registry","volume":"39","author":"Gjerstorff","year":"2011","journal-title":"Scand J Public Healt"},{"key":"2021080220014267700_keaa828-B43","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3899\/jrheum.140853","article-title":"Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy","volume":"42","author":"Aaltonen","year":"2015","journal-title":"J Rheumatol"},{"key":"2021080220014267700_keaa828-B44","doi-asserted-by":"crossref","first-page":"880","DOI":"10.3109\/0284186X.2012.698751","article-title":"Data quality at the Icelandic Cancer Registry: comparability, validity, timeliness and completeness","volume":"51","author":"Sigurdardottir","year":"2012","journal-title":"Acta Oncol"},{"key":"2021080220014267700_keaa828-B45","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.ejca.2008.10.037","article-title":"Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness","volume":"45","author":"Larsen","year":"2009","journal-title":"Eur J Cancer"},{"key":"2021080220014267700_keaa828-B46","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1002\/art.22808","article-title":"Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies","volume":"56","author":"Dixon","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2021080220014267700_keaa828-B47","doi-asserted-by":"crossref","first-page":"3833","DOI":"10.3390\/ijms20153833","article-title":"Current knowledge of the potential links between inflammation and prostate cancer","volume":"20","author":"Cai","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2021080220014267700_keaa828-B48","doi-asserted-by":"crossref","first-page":"259","DOI":"10.4081\/aiua.2017.4.259","article-title":"The association between prostatitis and prostate cancer. Systematic review and meta-analysis","volume":"89","author":"Perletti","year":"2017","journal-title":"Arch Ital Urol Androl"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/8\/3656\/39543583\/keaa828.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/8\/3656\/39543583\/keaa828.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T20:23:40Z","timestamp":1627935820000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/8\/3656\/6064849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,5]]},"references-count":48,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,1,5]]},"published-print":{"date-parts":[[2021,8,2]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa828","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,8,1]]},"published":{"date-parts":[[2021,1,5]]}}}